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Abstract
Allergic rhinitis is inflammation of the nasal mucosa resulting in a “runny” 
or “stuffy” nose, sneezing, itchy eyes, and other nonspecific upper 
respiratory symptoms. In current medical practice there are three ways to 
manage this condition including allergen avoidance, pharmacological 
management, and immunotherapy. This paper will explore the evidence 
regarding treatment of allergic rhinitis in adults, greater than 16 years of 
age (P), with subcutaneous immunotherapy (I) compared to long-term 
antihistamine use (C) with outcomes of reduced symptoms (O). 
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Introduction
Methods
Literature Search: November, 2019
Sources included PubMed, Web of Science, and Google Scholar
Search Terms: seasonal allergies AND allergen immunotherapy; 
subcutaneous allergen immunotherapy (search within: seasonal allergies)  
Inclusion Criteria: 
•Randomized control trial with human subjects 16+ years old 
•Review articles and observational studies 
•Published in the last 5-10 years in English 
Exclusion Criteria: 
•Research of sublingual immunotherapy route or vaccine development
• Study of dose response or tolerability 
• Focused on asthma as outcome measurement 
Future Research: 
• Length of symptom remission after immunotherapy +/- repeated 
courses of treatment 
• The effect of treatment duration (2 vs. 3 years) on patient symptoms  
Discussion 
Table 1. Comparison of study designs for subcutaneous allergen immunotherapy vs. pharmacotherapy 
Results 
1.  Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane 
Database of Systematic Reviews 2007, Issue 1. Art. No.: CD001936. DOI: 10.1002/14651858.CD001936.pub2.
2.  James LK, Durham SR. Update on mechanisms of allergen injection immunotherapy. Clinical & Experimental Allergy. 2008; 38(7):1074-1088. 
DOI:10.1111/j.1365-2222.2008.02976.x.
3.  Droessaert V, Timmermans M, Dekimpe E, et al. Real-life study showing better control of allergic rhinitis by immunotherapy than regular 
pharmacotherapy. Rhinology. 2016;54. doi:10.4193/Rhino14.282.
4.  Pfaar O, Urry Z, Robinson DS, et. al. A randomized placebo-controlled trial of rush preseasonal depigmented polymerized grass pollen 
immunotherapy. Allergy 2012; 67: 272-279. Doi: 10.1111/j.1398-9995.2011.02736. 
5.  Worm M, Rak S, Samoliński B, et al. Efficacy and safety of birch pollen allergoid subcutaneous immunotherapy: A 2-year double-blind, 
placebo-controlled, randomized trial plus 1-year open-label extension. Clin Exp Allergy. 2019;49:516–525. doi: 10.1111/cea.13331. 
6.  Bożek A, Krupa-Borek I, Jarzab J. Twenty years' observation of subcutaneous pollen allergoid immunotherapy efficacy in adults. Postepy Dermatol 
Alergol. 2017;34(6):561–565. doi:10.5114/ada.2017.72462. 
7.  Mosquera R, Martinez S, Montoro de Francisco A, et al. Satisfaction and perceived effectiveness in patients on subcutaneous immunotherapy 
with a high-dose hypoallergenic pollen extract. Eur Ann Allergy Clin Immunol. 2016;48(5):188-193.
8.  Rondón C, Blanca-López N, Campo P, et al. Specific immunotherapy in local allergic rhinitis: A randomized, double-blind placebo-controlled trial 
with Phleum pratense subcutaneous allergen immunotherapy. Allergy. 2017;73(4):905-915. doi:10.1111/all.13350.
9.  Niederberger V, Neubauer A, Gevaert P, et al. Safety and efficacy of immunotherapy with the recombinant B-cell epitope-based grass pollen 
vaccine BM32. J Allergy Clin Immunol. 2018;142(2):497–509.e9.doi: 10.1016/j.jaci.2017.09.052..
Efficacy of Subcutaneous Immunotherapy Compared to Pharmacotherapy in 
Decreasing Symptoms of Allergic Rhinitis in Adult Patients 
Subcutaneous immunotherapy is used for patients with severe and 
chronic allergic rhinitis that failed pharmacological management. The six 
studies analyzed found significant results with immunotherapy reducing 
patient symptoms, reducing patient medication use, improving patient 
quality of life, and inciting a positive immune response. However, 
insufficient statistical power and validity prevents these findings from 
changing standard of practice without further research that addresses 
these shortcomings. 
Conclusion
Key: PO = Prospective Observational; RSS = Rhinitis Symptom Score; ASS = Asthma Symptom Score; MS = Medication Score; RO = Retrospective 
Observational; VAS = Visual Analogue Scale; TNS = Total Nasal Symptoms; RCT = Randomized Control Trial; SMS = Combined Symptom and Medication 
Score, RQLQ = Rhinoconjunctivitis Quality of Life Questionnaire; NAPT = Nasal Allergen Provocation Test
1. Bożek et al (2017): Prospective observational study of 1006 
adults over 20 years to determine long-term efficacy of allergen 
specific immunotherapy as a possible cure. 
2. Droessaert et al (2016): Retrospective observational study of 
800 participants to evaluate degree of symptom control at 3 
years after receiving pharmacotherapy vs. immunotherapy
3. Mosquera et al (2016): Retrospective observational study of 
250 participants for the perceived effectiveness and satisfaction 
of subcutaneous immunotherapy Allergovit® from the 
participants’ point of view. 
4. Pfaar et al (2012): Randomized placebo-controlled trial of 
195 participants testing the efficacy of a rushed preseasonal 
SCIT of grass pollen extract, depigmented to avoid anaphylaxis 
5. Rondón et al (2017): Randomized double-blind placebo-
controlled 2 year trial of Phleum pratense (grass pollen) 
subcutaneous allergen immunotherapy for 56 adult subjects. 
6. Worm et al (2019): Randomized double-blind placebo-
controlled trial to study the efficacy of a high dose birch pollen 
immunotherapy in 253 subjects over 3 years. 
Overview: 
•Allergic rhinitis or “hay fever” cases continue to increase around the 
world, especially in developed countries with an average of ~30% adults
•Without a cure, it is an epidemiological and financial health care burden
•Allergen exposure in the mucous membranes lining the nose and upper 
respiratory tract à IgE-mediated inflammation reaction and delayed 
reaction 
Symptoms: watery nasal discharge, itching, occluded nose, sneezing, eye 
irritation, sinus pressure, etc.  
Treatment:
•Conservative: avoid allergen exposure
•Pharmacology: antihistamine, topical nasal steroid, systemic steroid, 
and/or decongestants 
• Immunotherapy: modifies the disease process 
Study Design Total N Age (years) Duration SCIT Dosing frequency Outcome 
measurements
Bożek et al 
(2017) 
PO 1006 Mean: 25.1 3 years SCIT,
1x a year F/U
3-year standard course: 
1. Allergovit® composition: 015 
grasses/cereals – 100%
2. Allergovit® composition: 
108 Birch – 35%, 
115 Alder – 30%, 
129 Hazel – 35%




et al (2016) 
RO 800 16-65 3 years SCIT 3-year standard course:
Maximum 3 allergen sources
1 Inj. SQ q1 week for 6 months




RO 250 5-65 3 years SCIT,  
1st 6-month F/U
0.6 ml 10,000 TU/ml strength Allergovit®
standard up-dosing schedule 
VAS, Satisfaction 
Questionnaire 
Pfaar et al 
(2012) 
RCT 195 18-55 2 years SCIT Depiquick® 1000 DPP/ml of 5 grass pollens, 
preseasonal rush schedule
1st visit: 0.2 and 0.3 mL at 30 min. intervals 
5 inj. q1 week of 0.5 mL
Maintenance dose of 31.5 ug Phl p 5  
SMS, RQLQ, well 
days, responder 
analysis, adverse 
events, and serum 
IgE, IgG4 levels 
Rondón 
et al (2017) 
RCT 56 18-55 2 years SCIT Depigoid® standard up-dosing schedule first 6 
months in the first year, 12 months in the 
second year  
2 up-dosing inj. 0.2 and 0.3 mL q30 mins for 
first visit, then 0.5 mL q4 weeks for 








NAPT, and serum 
IgG4 levels  
Worm et al 
(2019) 
RCT 253 18-60 3 years SCIT Allergovit® 1 injection q1 week standard up-
dosing schedule and 0.6 mL maintenance 
dose 
SMS, well days, 
serum IgG1 and 
IgG4 levels
Immunotherapy in the management of allergic rhinitis is established 
in research as an effective alternative to reduce symptoms and 
medication requirements for patients. Statistically significant results 
supporting subcutaneous immunotherapy were found in each of the 
articles based on different outcome measurements.  
Strengths Limitations 
• Objective data collection with 
serum immune marker IgG and 
IgE measurements 
• Measuring overall patient 
satisfaction 
• Observational: able to look at 
long periods of time 
• Small sample sizes for 
randomized control trials 
• Lack of follow-up appointment 
timelines 
• Observational: selection bias 
and recall bias for symptom 
reporting 
